IDT Biologika GmbH

EU Launches €225 Million Initiative to Accelerate Next-Generation Influenza Vaccine Development

- The European Union has committed €225 million to advance next-generation flu vaccines through clinical trials, representing the largest EU investment ever dedicated to accelerating innovative medical countermeasures. - This marks the first use of pre-commercial procurement by the European Commission to support vaccine candidates through clinical development, with contracts awarded to 10 organizations for 98-month development programs. - The initiative aims to develop vaccines that protect against broader influenza variants, can be rapidly adapted for pandemic strains, and offer alternative administration methods including nasal sprays, oral doses, and skin patches. - The funding addresses persistent scientific challenges in influenza vaccine development, where a 2025 review found that most critical milestones remain unresolved due to scientific complexity and resource constraints.